Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Raena Kaur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Fiona Stanley Hospital and PathWest Laboratory Medicine WA, Murdoch, Australia. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Cytopenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) is a common cause of morbidity after allogeneic haematopoietic cell transplantation (alloHCT). Pre‐emptive therapy (PET) with valganciclovir (VGC) is associated with haematological toxicity.
Methods
We included alloHCT patients from 2018 to 2021 where letermovir (LTV) was used for CMV PET because of cytopenias.
Results
Ten patients were included. Six received VGC prior to LTV. VGC was commenced at median d42, given for median 40 days. LTV was commenced at median d90, given for median 54 days. At commencement of antiviral, CMV viral load was higher for VGC at 3.7 log 10 IU/mL, compared to LTV at 2.9 log 10 IU/mL. Viral load reduction occurred at 0.18 log 10 IU/mL per week for VGC, compared to 0.17 log 10 IU/mL per week for LTV. There was no clinically significant CMV viremia after stopping LTV. Cytopenias improved on LTV.
Conclusion
LTV was effective in controlling CMV viremia when it was given at a lower starting CMV viral load and later post alloHCT than VGC. Further study is required of LTV as upfront PET following alloHCT. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Fiona Stanley Hospital and PathWest Laboratory Medicine WA, Murdoch, Australia.
- Department of Pharmacy, Fiona Stanley Hospital, Murdoch, Australia.
- Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Australia.
- Department of Microbiology, PathWest Laboratory Medicine WA, Murdoch, Australia.
ORCID-Profile: Peter Boan
Zitieren
APA
Kaur, R., Purtill, D., Cooney, J., Cannell, P., Wright, M., Copeland, T. S., McGuire, M., & Boan, P. (2023). Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease. https://doi.org/10.1111/tid.14147
Vancouver
Kaur R, Purtill D, Cooney J, Cannell P, Wright M, Copeland TS, et al. Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease. 2023. doi:10.1111/tid.14147
BibTeX
@article{Kaur2023,
author = {Kaur, Raena and Purtill, Duncan and Cooney, Julian and Cannell, Paul and Wright, Matthew and Copeland, Tandy-Sue and McGuire, Matthew and Boan, Peter},
title = {Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14147}
}
EUVIMED